Sonendo Inc Stock Price, News & Analysis

Sonendo (NYSE:SONX), a dental technology company specializing in the GentleWave® System, reported Q2 2025 financial results. Revenue was $7.4 million, down 11% year-over-year due to lower console sales from a streamlined sales team. The company showed operational improvements with gross margin increasing to 41% (up 320 basis points) and reduced loss from operations to $3.9 million.

Notable improvements include a 47% reduction in Adjusted EBITDA loss to $3.0 million and a 61% decrease in free cash flow burn to $2.6 million. The company maintained a cash position of $9.3 million with $14.2 million outstanding under its credit facility. Management reaffirmed 2025 guidance, projecting revenue of $31-32 million and gross margins of 44-46%.

Sonendo (SONX), a dental technology company specializing in the GentleWave System, reported Q1 2025 financial results with revenue of $7.4M, up 5% YoY. The company achieved significant improvements in key metrics, including gross margin expansion to 44% (up 1600bps YoY), 48% reduction in Adjusted EBITDA loss to $3.9M, and 58% reduction in free cash flow burn to $4.5M. Sonendo completed a $5M private placement and amended its credit facility to defer principal payments until at least September 2025. The company's cash position stood at $7.2M as of March 31, 2025, with $14.2M outstanding under its credit facility. Looking ahead, Sonendo provided guidance projecting 2025 revenue of $31-32M, gross margins of 44-46%, and expects to achieve positive adjusted EBITDA by 2028, with long-term goals including 65%+ gross margins and 9% CAGR through 2029.

Sonendo (SONX) has secured a $5.0 million private placement through the sale of 4 million common stock shares at $1.25 per share, representing a 10% premium to the recent closing price. The funding, supported by new and existing investors including company directors and officers, will be used to expand commercial programs, continue business restructuring, and improve working capital. Additionally, the company has amended its Credit Agreement with Perceptive Credit Holdings III, resulting in waived amortization payments for February and March 2025, and deferred payments from April 2025 to March 2026. CEO Bjarne Bergheim highlighted the company's progress in restructuring, stabilizing revenue, and reducing operating expenses, expressing confidence in further margin expansion and reduced losses in 2025.

Sonendo Inc. (SONX) reported its Q4 and full-year 2024 financial results, showing mixed performance with significant cost improvements despite revenue decline. Q4 revenue was $8.3 million, down from $9.0 million in Q4 2023, while full-year revenue reached $31.7 million, compared to $34.6 million in 2023.

Notable improvements include substantial gross margin expansion, with Q4 GAAP gross margin increasing to 41.1% from 25.4% year-over-year. The company significantly reduced its operating loss to $5.6 million in Q4 and $29.4 million for the full year, representing improvements of 45.2% and 50.4% respectively. Free cash flow burn decreased by 69.4% to $2.9 million in Q4.

The company maintains approximately 650 active customers for its GentleWave System. As of December 31, 2024, Sonendo had $11.6 million in cash and investments, with $15.1 million outstanding under its term loan facility.

Sonendo (OTCQX: SONX) reported Q3 2024 financial results with total revenue of $8.0 million, a 2% decrease from Q3 2023. The company showed significant improvements in margins, with GAAP gross margin rising to 41.2% and adjusted gross margin reaching 42.6%. Operating loss reduced to $7.5 million, while free cash flow burn improved by 59% year-over-year to $4.3 million. GentleWave console revenue decreased 10% to $1.9 million, maintaining an active user base of over 800 customers. The company ended the quarter with $17.3 million in cash and cash equivalents.

Sonendo (OTCQX: SONX), a dental technology company known for the GentleWave® System, has announced the postponement of its third quarter 2024 earnings conference call, which was originally scheduled for November 12th, 2024. While the company will proceed with filing its audited financial results on the planned date, management has delayed the accompanying conference call indefinitely. Commentary on post-quarter events will be provided at a later date.

Sonendo (OTCQX: SONX), a dental technology company and developer of the GentleWave® System, has scheduled its third quarter 2024 financial results announcement for November 12, 2024, after market close. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors can join via phone using specific dial-in numbers or access the live webcast through the company's investor relations website.

Sonendo (OTCQX:SONX) has launched ProControl™, a new software update for their GentleWave® G4 System designed to enhance endodontic care. The update enables endodontists to adjust procedure fluid concentration levels when using the CleanFlow™ procedure instrument, allowing for personalized treatment and improved clinical outcomes. ProControl offers optimized cleaning of complex anatomy and increased procedure efficiency, representing a significant advancement in dental technology. The system's unique ability to automatically and precisely adjust fluid concentrations during treatment sets it apart from other endodontic systems.

Sonendo, Inc. (OTCQX: SONX), a dental technology company, has entered into an Asset Purchase Agreement to acquire substantially all assets of Biolase, Inc. and its subsidiaries for $14 million, plus assumption of certain liabilities and settlement of ongoing patent litigation. Biolase filed for Chapter 11 bankruptcy on October 1, 2024. Sonendo will be designated as the "stalking horse" bidder in a Bankruptcy Court-supervised process, subject to higher offers and court approval.

Sonendo's CEO, Bjarne Bergheim, expressed commitment to ensuring a smooth transition for Biolase customers, patients, suppliers, and vendors. The company anticipates cross-selling opportunities and cost reduction synergies as a combined entity. In January 2023, Sonendo's subsidiary, PIPStek , filed a patent infringement lawsuit against Biolase, claiming damages of not less than $59,000,000.